Compare WEST & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEST | AUTL |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.6M | 433.8M |
| IPO Year | N/A | 2018 |
| Metric | WEST | AUTL |
|---|---|---|
| Price | $4.29 | $1.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $9.00 | $8.67 |
| AVG Volume (30 Days) | 509.4K | ★ 2.5M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,078,457,000.00 | $51,128,000.00 |
| Revenue This Year | $40.23 | $669.49 |
| Revenue Next Year | $15.67 | $91.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 28.89 | ★ 406.67 |
| 52 Week Low | $3.59 | $1.11 |
| 52 Week High | $7.92 | $2.70 |
| Indicator | WEST | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 54.87 |
| Support Level | $3.61 | $1.77 |
| Resistance Level | $4.16 | $2.07 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 89.73 | 46.39 |
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider in the U.S, providing coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice and restaurant, convenience store and travel center, non-commercial account, CPG, and hospitality industries around the world. The company's segment includes Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.